Effects of recombinant human serum albumin on ascites in rats with puromycin aminonucleoside-induced nephropathy.
1. Recombinant human serum albumin (rHSA) (1 g/kg) significantly decreased the weight of ascites in rats with puromycin aminonucleoside-induced nephropathy. 2. Furosemide (1-30 mg/kg) did not significantly reduce the weight of ascites in this model. 3. A combination of rHSA (1 g/kg) with furosemide (5 mg/kg) significantly decreased the weight of ascites in this model compared with furosemide alone. 4. In consideration of these results, rHSA can be a substitute for human serum albumin products prepared from human plasma in therapy for ascites or edema in furosemide-resistant nephrotic syndrome.
Central Research Laboratory, The Green Cross Corporation, Hirakata, Osaka, Japan. tsukada@yoshitomi.co.jp
M
M
Tsukada
M
M
Shintome
T
T
Matsui
H
H
Tsuchiyama
T
T
Maruyama
T
T
Yuki
S
S
Hanada
N
N
Nakamura
D000818:Animals; D001201:Ascites / Q000188:drug therapy; D004195:Disease Models, Animal; D004232:Diuretics / Q000627:therapeutic use; D004353:Drug Evaluation, Preclinical; D005665:Furosemide / Q000627:therapeutic use; D006801:Humans; D008297:Male; D009402:Nephrosis, Lipoid / Q000139:chemically induced / Q000188:drug therapy* / Q000652:urine; D009997:Osmotic Pressure; D011692:Puromycin Aminonucleoside / Q000633:toxicity*; D051381:Rats; D017208:Rats, Wistar; D011994:Recombinant Proteins / Q000627:therapeutic use; D012709:Serum Albumin / Q000627:therapeutic use*
D004232:Diuretics; D011994:Recombinant Proteins; D012709:Serum Albumin; D011692:Puromycin Aminonucleoside; D005665:Furosemide